CNSX:HUGE

FSD Pharma Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume4,870 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

FSD Pharma (CNSX:HUGE) Vs. SHOP, CSU, OTEX, LSPD, DSG, and KXS

Should you be buying HUGE stock or one of its competitors? Companies in the industry of "software - application" are considered alternatives and competitors to FSD Pharma, including Shopify (SHOP), Constellation Software (CSU), Open Text (OTEX), Lightspeed POS (LSPD), The Descartes Systems Group (DSG), and Kinaxis (KXS).

FSD Pharma (CNSX:HUGE) and Shopify (TSE:SHOP) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for FSD Pharma and Shopify, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FSD Pharma0000N/A
Shopify00403.00

Shopify has a consensus target price of C$1,835.00, indicating a potential upside of 21.25%.

Profitability

This table compares FSD Pharma and Shopify's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FSD PharmaN/AN/AN/A
ShopifyN/AN/AN/A

Valuation and Earnings

This table compares FSD Pharma and Shopify's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FSD PharmaN/AN/AN/AN/AN/A
ShopifyC$2.93 billion63.40C$398.35 millionC$3.25466.23

Shopify has higher revenue and earnings than FSD Pharma.

Summary

Shopify beats FSD Pharma on 2 of the 2 factors compared between the two stocks.

FSD Pharma (CNSX:HUGE) and Constellation Software (TSE:CSU) are both computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Profitability

This table compares FSD Pharma and Constellation Software's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FSD PharmaN/AN/AN/A
Constellation SoftwareN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for FSD Pharma and Constellation Software, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FSD Pharma0000N/A
Constellation Software05102.17

Constellation Software has a consensus target price of C$1,754.86, suggesting a potential downside of 7.70%.

Earnings & Valuation

This table compares FSD Pharma and Constellation Software's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FSD PharmaN/AN/AN/AN/AN/A
Constellation SoftwareC$3.97 billion10.15C$546.52 millionC$25.7973.72

Constellation Software has higher revenue and earnings than FSD Pharma.

Summary

Constellation Software beats FSD Pharma on 2 of the 2 factors compared between the two stocks.

Open Text (TSE:OTEX) and FSD Pharma (CNSX:HUGE) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Open Text and FSD Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Open Text01302.75
FSD Pharma0000N/A

Open Text presently has a consensus target price of C$58.60, suggesting a potential downside of 5.61%.

Earnings and Valuation

This table compares Open Text and FSD Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Open TextC$3.30 billion5.13$90.29 millionC$0.33187.55
FSD PharmaN/AN/AN/AN/AN/A

Open Text has higher revenue and earnings than FSD Pharma.

Profitability

This table compares Open Text and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Open TextN/AN/AN/A
FSD PharmaN/AN/AN/A

Summary

Open Text beats FSD Pharma on 2 of the 2 factors compared between the two stocks.

FSD Pharma (CNSX:HUGE) and Lightspeed POS (TSE:LSPD) are both computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares FSD Pharma and Lightspeed POS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FSD PharmaN/AN/AN/A
Lightspeed POSN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for FSD Pharma and Lightspeed POS, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FSD Pharma0000N/A
Lightspeed POS00603.00

Lightspeed POS has a consensus price target of C$93.86, suggesting a potential upside of 11.27%.

Valuation & Earnings

This table compares FSD Pharma and Lightspeed POS's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FSD PharmaN/AN/AN/AN/AN/A
Lightspeed POSC$175.60 million61.74C$-168,237,916.00C($1.31)-64.44

FSD Pharma has higher earnings, but lower revenue than Lightspeed POS.

Summary

Lightspeed POS beats FSD Pharma on 2 of the 2 factors compared between the two stocks.

The Descartes Systems Group (TSE:DSG) and FSD Pharma (CNSX:HUGE) are both computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Valuation & Earnings

This table compares The Descartes Systems Group and FSD Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Descartes Systems GroupC$348.66 million19.96$64.65 millionC$0.77107.66
FSD PharmaN/AN/AN/AN/AN/A

The Descartes Systems Group has higher revenue and earnings than FSD Pharma.

Profitability

This table compares The Descartes Systems Group and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Descartes Systems GroupN/AN/AN/A
FSD PharmaN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for The Descartes Systems Group and FSD Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Descartes Systems Group02202.50
FSD Pharma0000N/A

The Descartes Systems Group presently has a consensus price target of C$64.25, indicating a potential downside of 21.99%.

Summary

The Descartes Systems Group beats FSD Pharma on 2 of the 2 factors compared between the two stocks.

Kinaxis (TSE:KXS) and FSD Pharma (CNSX:HUGE) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares Kinaxis and FSD Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KinaxisC$224.19 million19.05$16.68 millionC$0.62255.93
FSD PharmaN/AN/AN/AN/AN/A

Kinaxis has higher revenue and earnings than FSD Pharma.

Analyst Ratings

This is a summary of recent recommendations for Kinaxis and FSD Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kinaxis00403.00
FSD Pharma0000N/A

Kinaxis currently has a consensus target price of C$199.00, suggesting a potential upside of 26.23%.

Profitability

This table compares Kinaxis and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KinaxisN/AN/AN/A
FSD PharmaN/AN/AN/A

Summary

Kinaxis beats FSD Pharma on 2 of the 2 factors compared between the two stocks.


FSD Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Shopify logo
SHOP
Shopify
1.0$1,513.38flatC$185.53 billionC$2.93 billion466.23
Constellation Software logo
CSU
Constellation Software
0.9$1,901.25flatC$40.42 billionC$3.97 billion73.72
Open Text logo
OTEX
Open Text
1.0$62.08flatC$17.05 billionC$3.30 billion187.55
Lightspeed POS logo
LSPD
Lightspeed POS
1.3$84.35flatC$11.43 billionC$175.60 million-64.44
The Descartes Systems Group logo
DSG
The Descartes Systems Group
0.7$82.36flatC$6.97 billionC$348.66 million107.66
Kinaxis logo
KXS
Kinaxis
1.2$157.65flatC$4.33 billionC$224.19 million255.93
Enghouse Systems logo
ENGH
Enghouse Systems
1.9$58.29flatC$3.28 billionC$512.22 million31.54
Real Matters logo
REAL
Real Matters
1.3$16.42flatC$1.40 billionC$472.46 million33.51News Coverage
PAT
Patriot One Technologies
0.7$2.40flatC$331.85 millionN/A-16.90News Coverage
Gap Down
PFM
ProntoForms
1.0$1.10flatC$96.06 millionC$17.67 million-68.75
ESP
Espial Group
0.5N/AN/AC$55.68 millionC$26.82 million-22.75
OSS
OneSoft Solutions
0.6$0.61flatC$52.35 millionC$4.06 million-20.33
MVP
MediaValet
1.2$2.56flatC$44.41 millionC$7.47 million-20.81
ITC
Intrinsyc Technologies
0.6N/AN/AC$35.07 millionC$24.88 million-54.69
PATH
CounterPath
0.6N/AN/AC$27.12 millionC$13.87 million39.25Gap Up
ROI
Route1
0.5$0.83flatC$26.49 millionC$30.88 million-118.57
BKD
Breaking Data
0.4$0.70flatC$20.07 millionC$9.47 million-1.46Gap Down
ILA
iLOOKABOUT Corp. (ILA.V)
0.6$0.59flatC$17.38 millionC$19.51 million-14.05
AXE
Acceleware
0.6$0.31flatC$14.77 millionC$899,281.00-15.50Gap Up
TLK
Frankly
0.7$0.44flatC$14.63 millionC$21.28 million4.23
DSY
Destiny Media Technologies
0.7$2.64flatC$10.12 millionC$4.03 million50.77Gap Up
ISD
iSIGN Media Solutions
0.5$0.06flatC$6.90 millionC$18,088.00-7.86
IQ
AirIQ
0.5$0.27flatC$6.56 millionC$3.75 million26.50Gap Up
EL
Engagement Labs
0.5$0.04flatC$4.64 millionC$3.27 million-1.75News Coverage
VIS
Visionstate
0.5$0.12flatC$3.16 millionC$148,936.00-8.85News Coverage
REW
RewardStream Solutions
0.5$0.14flatC$2.45 millionC$-313,671.00-4.00Gap Down
IVI
Ivrnet
0.5$0.07flatC$1.81 millionC$3.05 million-2.41
PROS
ProSmart Enterprises
0.6$0.04flatC$1.29 millionC$74,364.00-0.20Gap Down
BLOX
(BLOX)
0.4N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
SAAS
(SAAS)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
SPO
16580
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
GET
178110
0.6N/AN/A$0.00N/A0.00Gap Up
1mage Software logo
ISOL
1mage Software
0.7N/AN/A$0.00N/A0.00
FDM
Fandom Sports Media
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
RIW
Riwi
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.